Clinically, some postoperative adjuvant treatments are aimed at eradicating residual tumor cells in situ and in other sites of the body where mDTCs are hidden, such as the use of estrogen receptor antagonists to prevent the growth of hormone-dependent tumor cells. This evidence concerns the gene ESR1 and neoplasm.